Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St set to open higher as chip stocks extend recovery; earnings in focus
- Oil prices rise nearly 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Acceleron Pharma (XLRN) Misses Q3 EPS by 2c
November 3, 2016 5:01 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.55), $0.02 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.08 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
... More